ORKA
The table below shows Oruka Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$88.21M | -$57.84M | -$5.01M | -$10.91M | -$18.76M | -$7.72M |
| Capital expenditure | $209.00K | $189.00K | $0.00 | $2.00K | $43.00K | $19.00K |
| Investing cash flow | -$96.75M | -$330.13M | $0.00 | -$2.00K | -$43.00K | -$19.00K |
| Dividends paid | - | - | - | - |
Oruka Therapeutics, Inc. reported operating cash flow of -$88.21M for fiscal year 2025. That is down 52.5% from -$57.84M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$5.29M (FY 2013) to -$88.21M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $170.31M | $449.54M | $0.00 | $0.00 | $23.09M | $48.45M |